Zobrazeno 1 - 10
of 4 633
pro vyhledávání: '"Pertuzumab"'
Autor:
Dai Okemoto, Toshifumi Yamaguchi, Mariko Yamaguchi, Toru Kadono, Hiroki Yukami, Elham Fakhrejahani, Hiroki Nishikawa
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 1001-1007 (2024)
Introduction: In recent years, trastuzumab and pertuzumab have been used in treatment protocols for patients with HER2-positive colorectal cancer. Although severe thrombocytopenia is an uncommon side effect of anti-HER2 antibody therapy, we present t
Externí odkaz:
https://doaj.org/article/1642784669d742c396cf1d2633a51794
Autor:
Fabio Canino, Monica Barbolini, Ugo De Giorgi, Tommaso Fontana, Valeria Gaspari, Caterina Gianni, Lorenzo Gianni, Antonio Maestri, Santino Minichillo, Luca Moscetti, Antonella Mura, Stefania Vittoria Luisa Nicoletti, Claudia Omarini, Rachele Pagani, Samanta Sarti, Angela Toss, Claudio Zamagni, Riccardo Cuoghi Costantini, Federica Caggia, Giuseppina Antonelli, Federica Baglio, Lorenzo Belluzzi, Giulio Martinelli, Salvatore Natalizio, Ornella Ponzoni, Massimo Dominici, Federico Piacentini
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-18 (2024)
Abstract Background The addition of pertuzumab (P) to trastuzumab (H) and standard chemotherapy (CT) as neoadjuvant treatment (NaT) for patients with HER2 + breast cancer (BC), has shown to increase the pathological complete response (pCR) rate, with
Externí odkaz:
https://doaj.org/article/1ac6fc48a61047d696aefc89f35bee02
Autor:
Sherko Kuemmel, Catherine Harper-Wynne, Yeon Hee Park, Fábio Franke, Michelino de Laurentiis, Eva Schumacher-Wulf, Daniel Eiger, Sarah Heeson, Andrés Cardona, Özgür Özyilkan, Flavia Morales-Vàsquez, Ciara Metcalfe, Marc Hafner, Eleonora Restuccia, Joyce O’Shaughnessy
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background HER2-positive, estrogen receptor-positive breast cancer (HER2+, ER+ BC) is a distinct disease subtype associated with inferior response to chemotherapy plus HER2-targeted therapy compared with HER2+, ER-negative BC. Bi-directional
Externí odkaz:
https://doaj.org/article/e5f45a7c5b7e4bb7bb99b0bb30af3b2c
Autor:
Luciana Castro Garcia Landeiro, Tamie de Camargo Martins, Ruth Bartelli Grigolon, Isabel Monteiro, Joana Bisol Balardin, Eduardo Padilha, Gilberto Amorim, Stephen Stefani
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
IntroductionBreast cancer (BC) is one of the leading causes of cancer and is the first cause of death from malignant tumors among women worldwide. New cancer therapies receive regulatory approval yearly and to avoid health disparities in society, the
Externí odkaz:
https://doaj.org/article/4658c43d9b634fe9a44fd94670a6fb0d
Autor:
Zheng Wang, Yu Liu, Yunxia Xu, Lin Lu, Zhen Zhu, Baojie Lv, Xin Fang, Yao Tang, Jinhua Wang, Yu Cheng, Ying Hu, Junwen Lou, Peican Wu, Chendan Liu, Yanjun Liu, Xin Zeng, Qing Xu
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
Currently approved human epidermal growth factor receptor 2 (HER2)-targeted antibody therapies are largely derived from trastuzumab, including trastuzumab-chemotherapy combinations, fixed-dose trastuzumab-pertuzumab combinations, and trastuzumab anti
Externí odkaz:
https://doaj.org/article/7d08bc471b9245bea159a6d008edd6d0
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Heliyon, Vol 10, Iss 14, Pp e34511- (2024)
Breast cancer (BC) is the prevailing malignancy among women, with HER2 overexpression observed in 20–30 % of all BC, thereby serving as a prognostic indicator for unfavorable outcomes in affected individuals. There is a necessity to establish innov
Externí odkaz:
https://doaj.org/article/f85136537d17470b83d741daf4d7710d
Autor:
LIU Yunjiang, YANG Chao
Publikováno v:
Zhongliu Fangzhi Yanjiu, Vol 51, Iss 1, Pp 12-15 (2024)
Neoadjuvant therapy is a preoperative systemic treatment for patients with breast cancer. This therapy has greatly improved the clinical outcomes of human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which is associated with poor
Externí odkaz:
https://doaj.org/article/4533eafae39740199557c79f445d5e8b
Autor:
Nianhua Ding, Jian Pang, Xuan Liu, Xiongbin He, Wei Zhou, Haiqing Xie, Jianqi Feng, Guo Wang, Jie Tang, Jing Cao, Liying He, Yingjian He, Shouman Wang, Zhi Xiao
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-10 (2024)
Abstract Purpose This study aimed to evaluate the prognostic role of the baseline neutrophil/lymphocyte ratio (NLR) in HER2-positive metastatic breast cancer (MBC) patients treated with trastuzumab/pertuzumab. Experimental design Data from 780 patien
Externí odkaz:
https://doaj.org/article/3479d1ded519474488b5ce32f8c28ae9
Autor:
Ayelén Ivana Pesce Viglietti, María Belén Bordignon, Alexis Ostinelli, Manglio Miguel Rizzo, Gerardo Cueto, María Belén Sanchez, Florencia Perazzo, Mora Amat, Federico Coló, María Victoria Costanzo, Adrián Nervo, Jorge Nadal, Gabriel Crimi, Ignacio Mc Lean, Eunice Amancay Spengler, José Mordoh, Pablo Mandó, Estrella Mariel Levy
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 17, p 9268 (2024)
Currently, therapy for early-stage human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) is based on the combination of trastuzumab and pertuzumab plus chemotherapy in a neoadjuvant regimen. The INMUNOHER study aimed to detect
Externí odkaz:
https://doaj.org/article/d6c1e774ca4b49c8941b609b2ef344a6